[Skip to Navigation]
Views 1,802
Citations 0
Research Letter
October 15, 2020

Early Trastuzumab Interruption and Recurrence-Free Survival in ERBB2-Positive Breast Cancer

Author Affiliations
  • 1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
  • 2SUNY Downstate Medical Center, Brooklyn, New York
  • 3Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer, New York, New York
  • 4Weill Cornell Medical College, New York, New York
JAMA Oncol. 2020;6(12):1971-1972. doi:10.1001/jamaoncol.2020.4749

Human epidermal growth factor receptor 2 (ERBB2)-targeted therapies such as trastuzumab improve disease-free and overall survival for patients with ERBB2-positive breast cancer (BCA).1 Cardiotoxic effects, characterized by reduced left ventricular ejection fraction (LVEF) or clinical heart failure (HF), are an important treatment-limiting adverse effect of ERBB2-targeted therapy and the most common indication for early trastuzumab interruption.2 Findings from the PHARE and PERSEPHONE trials on the noninferiority of 6- vs 12-month durations of trastuzumab are conflicting, thus the clinical significance of early trastuzumab interruption on BCA outcomes remains uncertain.3,4 Our primary objective was to evaluate the association of early trastuzumab interruption with BCA outcomes in clinical practice.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×